Conducting clinical research studies with
Call to participate

Archive for the ‘ Dr. Radin ’ Category

Mobile Memory Clinic

Thursday, October 1st, 2015


Residents of Hamilton Park

Residents of Hamilton Park

CCRstudies had the pleasure of taking our show on the road to kick off the month of October.  We conducted a presentation on Alzheimer’s research at the Hamilton Park Apartments in Norwich.  Following the presentation, free memory screenings were held for interested residents as part of the Alzheimer’s Foundation of America’s early detection/screening initiative.

Residents in attendance were gracious and attentive and not only appreciated the information presented, but also had some fun with our free giveaways!  The Alzheimer’s presentation was interactive, and residents asked questions throughout such as “if I lose my keys all the time, does this mean I am losing my mind?” and, “what’s the difference between being senile, having dementia, and having Alzheimer’s?”  People shared their stories of caring for loved ones with Alzheimer’s, and noted how eager they were to participate in the early detection memory screening. Virtually all in attendance had an anecdote to share about someone in their life living with memory disease.  A big “thank you” goes out Tara Dowling of Hamilton Park who invited us to facilitate the event.  We look forward to further connecting with the Norwich community!

Alzheimer’s Talk on the Air

Monday, August 31st, 2015

Recently, CCRstudies had the good fortune of going on the Lee Elci Radio Show on 94.9 News Now.  Lee, an affable host, allowed CCR’s MaryLou Gannotti, Public Relations and Communications Director, to have an open discussion on Alzheimer’s Disease, including promoting CCRstudies no cost memory testing through the Alzheimer’s Foundation of America. MaryLou also talked about the STARBEAM study, a clinical research trial testing an investigation add-on medication for those living with mild to moderate Alzheimer’s Disease.

To hear more, click on the play button below:

To learn more about CCRstudies Free Memory Testing, or the STARBEAM study, call 860-443-4567 or email

Memory Screenings

Thursday, July 16th, 2015
These two adorable ladies were among the many individuals we met at the Southeast Healthy Living Expo.

These two adorable ladies were among the many individuals we met at the Southeast Healthy Living Expo.

CCRstudies recently provided a valuable service to the community thanks to offering no cost memory screenings at the recent Southeast Healthy Living Expo. The event was held at Norwich Technical High School in Norwich, and featured a variety of booths offering services to the senior community and general community.  Diane Palmer, R.N., CCRC, and Qualified Dementia Care Specialist through the Alzheimer’s Foundation of America, conducted the individual memory screenings with those at the event who expressed interest.  20 people participated in the memory screenings, which for some, proved to provide invaluable information regarding the next steps to take in terms of the detection and diagnosis of memory disease.

While progress continues to be made in treating memory disease thanks to the clinical trial process, no cure exists for Alzheimer’s.  No new drugs to treat Alzheimer’s have been approved in the last 10 years.

CCRstudies hope to expand upon the success of our recent no cost memory screenings as we look forward to further engaging members of the community in regards to this service.  We encourage interested individuals and groups to contact us about this service.

To learn more about no cost memory screenings, or the STARBEAM Study for Alzheimer’s Disease, currently being conducted at CCRstudies, call 860-443-4567, or e-mail

Jessie Jellison, LPN, Q.D.C.S

Monday, June 22nd, 2015
Jessie Jellison, LPN, chats with Jocelyn Maminta of WTNH News 8.

Jessie Jellison, LPN, chats with Jocelyn Maminta of WTNH News 8.

Congratulations to CCRstudies team member Jessie Jellison, LPN, CRC and now – Q.D.C.S.  Jessie has earned the distinction through the Alzheimer’s Foundation of America as being recognized as a Qualified Dementia Care Specialist.  Jessie successfully completed the Dementia Care Professionals of America’s (DCPA) Series I and II training programs.

Jessie’s new distinction represents the highest level of qualification offered by DCPA.  She is currently using her skills in memory care as part of the research team for the STARBEAM study, a clinical trial being conducted at CCRstudies in New London for people with mild to moderate Alzheimer’s disease.

The Alzheimer’s Foundation of America’s mission is to provide optimal care to persons with Alzheimer’s disease and related illnesses, as well as their families.  We are proud of Nurse Jessie for her hard work and proud to be affiliated with the Alzheimer’s Foundation of America.


Alzheimer’s Disease Study

Tuesday, June 16th, 2015


Help us reshape the treatment for Alzheimer’s disease

Are you or is someone you know diagnosed with Alzheimer’s disease AND is donepezil, rivastigmine or galantamine the current treatment? If yes, we invite you to continue reading.

While there is no known cure for Alzheimer’s, in recent years thanks to clinical trials, advances have been made. But more medicines are needed to provide patients, caregivers and their physicians with treatment choices.

Currently three studies are underway to investigate whether a research drug called idalopirdine, given in addition to the Alzheimer’s medicine, donepezil, rivastigmine or galantamine, improves brain functioning in areas such as memory, thinking and reasoning.

Idalopirdine is being jointly developed by Lundbeck and Otsuka Pharmaceutical. Lundbeck is conducting a series of three clinical research studies for Alzheimer’s called the STAR studies.

The aim of the three STAR studies:

• Test if a new type of drug works and how safe it is in patients with Alzheimer’s disease.• Investigate the safety and effectiveness of the drug idalopirdine at varying doses

It is important to note that idalopirdine has already been tested in clinical studies with promising results.

Why Clinical Research Depends on People like You

Without the valuable participation of people like you, clinical research for Alzheimer’s treatments cannot be developed. We appreciate you taking the time to consider whether participation in an Alzheimer’s clinical research study might be an option for you or the person you know with Alzheimer’s.

By taking part in this clinical research study, you and others like you will be helping to evaluate an investigational drug to determine its safety and effectiveness for Alzheimer’s patients with mild to moderate symptoms when used with another Alzheimer’s medicine.

About This Study

We invite you to learn about a clinical research opportunity for Alzheimer’s. Access to this clinical research study is available to Alzheimer’s patients globally whose medical history matches the requirements of the study.

Study Purpose:

The aim of the STAR clinical trials is to test how well a new type of drug works and how safe it is in patients with mild to moderate Alzheimer’s disease.

The investigational treatment is known as idalopirdine. It is believed to work by helping nerve cells in the brain work together, which is very important for memory, thinking and reasoning.

In the STAR studies, patients will be selected to receive different doses of idalopirdine or placebo (a dummy capsule that has no active ingredient), in addition to continuing to take their donepezil, rivastigmine or galantamine.

Comparing drugs with placebo is the only way for the doctors to tell if idalopirdine is having an additional effect on mental functioning.

Even if your loved one is assigned to the placebo group, they will still remain on their current Alzheimer’s treatment throughout the STAR study.

Additionally, at the end of the study, participants may have an opportunity to continue in a

6-month extension study where all patients receive idalopirdine along with donepezil, so if the Alzheimer’s patient was assigned to the placebo group, they may be able to try the new drug later.

What to Expect

The doctors conducting the STAR studies need to be able to track the effectiveness of idalopirdine. To do this, it is important to conduct some tests before the study drug is administered. Doctors can then see if there are changes during treatment or not.

A number of tests will be used to check memory, language, reading and figure-copying (some of them will be audio- and/or video-recorded). The Alzheimer’s patient will also be asked questions about how they are feeling and coping with daily life.

A brain scan is required (if the Alzheimer’s patient has not had one within the last 12 months).

Blood and urine tests will be done periodically to measure various things, such as liver and kidney function and the amount of study drug in the blood stream (following enrollment in the study).

Blood pressure, pulse and weight data will be taken, and ECGs will be performed to monitor heart function. These last about 10 minutes and are generally not painful.

STAR Study Design

Clinical trials require significant oversight, and this translates to close monitoring and medical care.

If a brain scan is needed, this will be completed prior to start of the study treatment. Once study treatment is started, 8 assessment visits are required. This translates to one visit approximately every 4 to 6 weeks during the study.

On the 2nd, 3rd, 4th, 5th and 6th visits, the next medicine pack is provided along with specific medical tests (explained in the ‘What to Expect’ Section of this website).

This means that 8 sets of tests will be conducted during the study, including ECGs and blood tests, (unless any retests are needed). Each blood test requires about 3 teaspoons of blood.

If the Alzheimer’s patient is unable to attend all study related visits or adhere to the study’s medication plan, it is important to think carefully about being involved, and give someone else an opportunity to participate in one of the STAR studies instead.

The patient’s caregiver must be able to attend all appointments, since their input is collected during each study visit.

Why Participate?

Every study participant makes a difference

As a study participant, Alzheimer’s patients and their caregivers have access to a healthcare team who may help you understand Alzheimer’s better. In addition, the information gathered from the STAR studies will contribute to greater knowledge about treatment options in Alzheimer’s for future generations. This is important since there is a significant body of evidence suggesting that Alzheimer’s has a genetic link.

Benefits to Study Participants:

There are many benefits to participating in the STAR studies. We have listed some of these reasons below:

• All study-related medicines and consultations specific to the study will be free of charge and reasonable travel, parking and food expenses will be paid• Transportation assistance may be provided to and from study visits

• The patient may continue to see their regular doctor while participating in a STAR Alzheimer’s study

• In the US, health insurance is not required to participate in a STAR Alzheimer’s study

• A high standard of study-related medical care will be provided

• Patients may help to advance a potential new treatment for mild to moderate Alzheimer’s disease

• Patient may have an opportunity to continue in a 6-month extension study where all patients, even those on placebo, will receive idalopirdine and donepezil.


Further details regarding study participation will be supplied by the study center during the screening process. See if you pre-qualify for this clinical trial opportunity, and join others in potentially advancing a new investigational medication for mild to moderate Alzheimer’s.

Laurence Radin, MD will serve as Primary Investigator of the STARBEAM study in New London. He is a board certified neurologist and has been in practice with Neurologic Group PC  since 1992.  In his role as a CCRstudies Investigator, Dr. Radin has worked on clinical trials for Alzheimer’s disease, Parkinson’s, Diabetic Peripheral Neuropathy, and others.

Call CCRstudies at 860-443-4567 to learn more about the STARBEAM for Alzheimer’s Disease.

DPN Study

Monday, May 4th, 2015

Over half of all those living with Type II Diabetes will develop DPN.

DPN, or Diabetic Peripheral Neuropathy, is a condition that results due to chronically high blood sugar levels resulting in nerve damage.  Symptoms of DPN can include pain, numbness and tingling in the feet, discomfort, and burning sensations.  Due to nerve damage, complications can arise for the individual living with DPN.

Diabetes has been described as a global epidemic, with nearly 26 million Americans living with the condition. Poor diet, lack of exercise, and increasing obesity rates are often to blame for the Type II diabetes crisis in the US.

CCRstudies has been enrolling eligible volunteers for a study looking at the effectiveness of a nutritional food in the treatment of diabetic foot pain.  The nutritional therapy, Metanx, is a FDA approved medication containing a combination of the active forms of folic acid, vitamin B6 and vitamin B12. These vitamins are said to work together to increase blood flow to the nerves.

Metanx differs from standard over the counter vitamins since it is considered a “medical food.” Medical foods have been specially formulated to address distinct nutritional requirements of a specific disease or condition. Metanx is only available by prescription.

The study team consists of Edward J. McDermott, Jr MD, Laurence Radin MD, Andrea Stewart, APRN, Diane Palmer, RN, CCRC, Jessie Jellison, LPN, CRC and Carol Alexandrescu, MS, CRC.

Those interested in learning more about the DPN study can call 860-443-4567.

Alzheimer’s Research

Monday, August 25th, 2014

Geras Study Flyer

Have You or a Loved One Received Care for Memory Impairment?

A Study for Patients with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease

A research study is being conducted to gather information about caring for patients diagnosed with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease.

Patients may qualify for the study if they:

  • Are between 55 and 85 years old
  • Have a reliable family member or friend willing to serve as a study partner and attend all study visits

If you choose to participate in this study, you will help us to collect information that may help others affected by Alzheimer’s disease in the future.

Study Team: Dr. Laurence Radin, Andrea Stewart APRN, Diane Palmer RN

Call (860)443-4567 to learn more or email





Alzheimer’s Disease Clinical Trial Announced

Thursday, July 3rd, 2014

cropped Radin's Ateam


Adults under the age of 90 who have been diagnosed with mild or moderate Alzheimer’s disease, or undiagnosed individuals experiencing noticeable memory loss may be eligible to participate in a clinical trial for Alzheimer’s disease currently being conducted at CCRStudies in New London, Connecticut. The study will include a free memory screening.

This clinical trial research program, led by Dr. Laurence Radin of Neurological Group, PC in New London, is examining an investigational medication being developed to slow or halt the progression of Alzheimer’s disease. Fellow researchers include Andrea Bartels APRN, and Andrea Stewart APRN. According to Dr. Radin, “this research will ideally bring us closer to a cure for Alzheimer’s, and will help to give hope to the individuals and families affected by Alzheimer’s.” The trial is being sponsored by TauxRx Therapeutics.

More than five million Americans are currently living with Alzheimer’s disease and there is no cure. Approximately 200,000 Americans under the age of 65 have younger onset Alzheimer’s. Alzheimer’s is a progressive, degenerative disorder that attacks the brains nerve cells, resulting in loss of memory, loss of thinking and language skills, and behavioral changes.

“People suffering from memory loss and those around them will tell you how devastating this disease can be,” said Dr. Radin.

CCRStudies is seeking volunteer participants for the current clinical trial. Those who become eligible for the trial will receive study related care and psychological testing at no cost. Reimbursement for time and travel may be available. No insurance is needed to participate in the clinical trial.

For a preliminary phone evaluation, interested individuals can contact CCRStudies at 860-443-4567. Those looking for more information can also visit

Alzheimer’s Clinical Research Study

Tuesday, June 17th, 2014

Help your loved one join the TauxRx clinical trial for Alzheimer’s Disease. This clinical trail research program is examining an investigational medication being developed to slow or halt the progression of Alzheimer’s disease.

Who can take part?  Adults under the age of 90  Diagnosed with mild or moderate Alzheimer’s disease  Undiagnosed and experiencing noticeable memory loss

Participants will receive –  Study-related care and psychological testing at no cost  Study conducted by: Dr. Laurence Radin, Andrea Bartels APRN, Andrea Stewart APRN, Elena Schjavland APRN  Call CCRstudies at  (860) 443-4567

*Reimbursement for time and travel may be available

No insurance needed

19May2014 Print with IRB changes - Copy

Diabetic Neuropathy Research Study

Tuesday, June 17th, 2014

Do you have numb, tingling painful feet due to DPN?

CCRstudies is seeking individuals to participate in Diabetic Peripheral Neuropathy (DPN) research study of Matanx in addressing DPN symptoms.

To qualify you must:

Be between the ages of 25 to 80

Have a diagnosis of Type II Diabetes

Have established DPN for over 6 months but less than 7 years

Qualified participants will receive at no cost, study related:

Investigational medication or placebo

Diagnostic and routine lab testing at no cost.

For more information call: 860-443-4567